UPDATED 6/11/2012 2:30 p.m. with comment from Edwards
Edwards Lifesciences
Edwards Lifesciences wins FDA okay for new GLX heart valve trial
Edwards Lifesciences (NYSE:EW) won FDA approval to begin human clinical trials of a new heart valve tissue treatment process that may make the implants more durable.
MassDevice.com +3 | The top 3 med-tech stories for May 29, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Recalls: Edwards pulls Perimount heart valves over packaging concerns
Edwards Lifesciences (NYSE:EW) issued a recall of certain lots of Perimount replacement heart valves over concerns that they may have been contaminated with "extremely small" metallic particles during packaging.
EuroPCR: Sapien win, promising post-approval results weigh in Edwards’ favor
Leerink Swann analysts saw promise in a pair of "tidbits" about Edwards Lifesciences’ (NYSE:EW) Sapien XT transcatheter aortic valve implantation system presented at the EuroPCR conference in Paris this week.
EuroPCR: Warnings on TAVI in replacing surgically implanted prosthetic valves
Although patients may benefit from having a failed aortic valve prosthetic reinforced via transcatheter aortic valve implantation, researchers warned against making the procedure a common practice.
Edwards CEO Mussallem announces stock plans | Personnel Moves
St. Jude Medical’s largest backer boosts stake by 30% | Wall Street Beat
St. Jude Medical‘s (NYSE:STJ) largest investor boosted its stake by more than 30%, to some 27.2 million shares, or about 10% of the medical device maker.
MassDevice.com +7 | The top 7 med-tech stories for the week of April 30, 2012.
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.
MassDevice.com +3 | The top 3 med-tech stories for May 2, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.